The effect of danazol in the treatment of chronic cystic mastitis.

Obstetrics and gynecology · 1976 · vol. 48(1) , pp. 93–8 · PMID:945522 · W2286039708
article OA: closed CC0 ⤵ 29 in-corpus citations
View on OpenAlex View on PubMed
AI-generated summary by claude@2026-06, 2026-06-08

Danazol treatment of 40 chronic cystic mastitis patients at 400 mg daily resulted in marked symptom improvement in 87.5%, with mild weight gain as the major side effect and no significant changes in hormone levels.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Danazol in a dose of 400 mg daily was administrated to 40 patients with chronic cystic mastitis and resulted in a marded improvement in both objective and subjective symptoms in 87.5% of the patients studied. Three patients showed partial relief of symptoms and 1 patient showed no improvement after 1 month of treatment at which time she withdrew from the study. One patient had a worsening of her condition and was withdrawn from the study after 3.5 months of therapy. Nineteen of the 40 patients in the study had a secondary diagnosis of pelvic endometriosis confirmed histologically, and all these patients showed a marked improvement of symptoms during the Danazol treatment. Patients developed amenorrhea after 3 to 4 months of Danazol therapy, and symptoms such as dysmenorrhea, premenstrual pelvic pain, and tension abated at the same time. A mild, but well-tolerated weight gain was the major side effect of Danazol administration. No significant changes in the levels of plasma E1, E2, FSH, LH, or progesterone could be demonstrated in specimens drawn from 11 patients before and during the course of Danazol administration.

My notes (saved in your browser only)

Condition tags

endometriosisdysmenorrhea

MeSH descriptors

Danazol Mastitis Pregnadienes Administration, Oral Adult Body Weight Body Weight Chronic Disease Cysts Cysts Danazol Danazol Danazol Drug Evaluation Endometriosis Endometriosis Endometriosis Female Humans Mastitis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (29)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-14T05:58:58.463083+00:00
License: CC0 · commercial use OK